Orientador: Claudio Chrysostomo Werneck / Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-27T06:06:14Z (GMT). No. of bitstreams: 1 Pereira_CatherineNatalia_M.pdf: 4403950 bytes, checksum: 7142bd3654bd7f9d99e12cda4d33aeeb (MD5) Previous issue date: 2015 / Resumo: Fibrilina-1 (FBN-1) é um importante componente da rede de microfibrilas da matriz extracelular (MEC). As microfibrilas estão presentes nas fibras elásticas que são responsáveis pela resiliência de tecidos como pulmões, pele e grandes vasos. Mutações no gene da fibrilina-1 estão associadas à Síndrome de Marfan, doença autossômica dominante, caracterizada por uma desordem do tecido conjuntivo. Pacientes com esta Síndrome apresentam anomalias no sistema esquelético e trato cardiovascular. Dados da literatura relacionam a menor quantidade de FBN-1 na MEC com a atividade exacerbada do TGF-? promovendo a quase totalidade das alterações fenotípicas encontradas. Estudos preliminares em nosso laboratório com camundongos que possuem menor quantidade de FBN-1 de um camundongo normal tem demonstrado que necessitam do dobro do tempo para a formação de trombo em um modelo de trombose arterial. As plaquetas tem fundamental importância neste processo, quando são ativadas secretam várias moléculas que determinam a formação dos trombos. Realizamos um estudo comparativo do proteoma de plaquetas e da artéria aorta de camundongos selvagens e deficientes em FBN-1, através da técnica de eletroforese bidimensional (2DE) juntamente com a espectrometria de massas a fim de encontrar diferenças no perfil proteico que justificassem tais sintomas. Diversas proteínas plaquetárias foram encontradas apenas no grupo controle, como endoplasmina, fator de von Willebrand, calpaína, dentre outras; assim como a proteína vinculina foi encontrada apenas no grupo deficiente em FBN-1. Todas as proteínas encontradas podem ser de grande interesse para o esclarecimento a respeito do maior tempo de formação de trombo e os sintomas relacionados à Síndrome de Marfan / Abstract: Fibrillin-1 (FBN-1) is an important microfibril network component of extracellular matrix (ECM). Microfibrils are present in elastic fibers responsible for tissues resiliency, such as lungs, skin and great vessels. Mutations in fibrillin-1 gene are associated with Marfan Syndrome, a dominant autosomal disease characterized by connective tissue disorder. Patients with this syndrome show abnormalities in skeletal system and cardiovascular tract, aorta dilatation and aneurysms. Literature data relate less FBN-1 in the ECM with TGF-? heightened activity, promoting almost all the phenotypic alterations. Preliminary studies in our laboratory demonstrated that mice containing half amount of FBN-1 presented prolonged thrombosis time when compared to wild-type mice submitted to an arterial thrombosis model. Platelets are important in this process, when activated they release several molecules and factors which determine thrombi formation. We conducted a comparative proteome study of platelet and aorta from wild-type against FBN-1 deficient mice by two-dimensional electrophoresis (2DE) coupled with mass spectrometry in order to find some differences in protein profile that could justify such symptoms. Several platelet proteins were found only into control group, as endoplasmin, von Willebrand factor, calpain; as well as vinculin was found only in the FBN-1 deficient group. All proteins found may have great interest for understanding the prolonged thrombus formation time, and symptoms related to Marfan Syndrome / Mestrado / Bioquimica / Mestra em Biologia Funcional e Molecular

Cysteinyl leukotriene receptor 2, a G-protein coupled receptor known to be expressed and functional on human platelets. However, it seems that upon ligand activation the cysteinyl leukotriene receptor 2 activates a variety of signaling pathways in multiple cell types among different species. Previously, a former laboratory member Vrinda Kulkarni found cysteinyl leukotriene receptor 2 to be expressed on the surface of adult zebrafish thrombocytes. In this work I studied the characteristics of aggregation in adult zebrafish thrombocytes with the knockdown of cysteinyl leukotriene receptor 2. I used a newly developed knockdown method to study the function of cysteinyl leukotriene receptor 2. Knockdown of the cysteinyl leukotriene was confirmed using RT-PCR results showed p=.001, reduced sell surface level of expression of the cysteinyl leukotriene receptor 2 results showed that p=.002. I found that the knockdown of cysteinyl leukotriene receptor 2 results in prothrombotic thrombocytes by using flow cytometry p=.0001.

Thrombocytes are functional equivalents of mammalian platelets and also possess megakaryocyte features. It has been shown earlier that hox genes play a role in megakaryocyte development. Our earlier microarray analysis showed five hox genes, hoxa10b, hoxb2a, hoxc5a, hoxc11b and hoxd3a, were upregulated in zebrafish thrombocytes. However, there is no comprehensive study of genome wide scan of all the hox genes playing a role in megakaryopoiesis. I first measured the expression levels of each of these hox genes in young and mature thrombocytes and observed that all the above hox genes except hoxc11b were expressed equally in both populations of thrombocytes. hoxc11b was expressed only in young thrombocytes and not in mature thrombocytes. The goals of my study were to comprehensively knockdown hox genes and identify the specific hox genes involved in the development of thrombocytes in zebrafish. However, the existing vivo-morpholino knockdown technology was not capable of performing such genome-wide knockdowns. Therefore, I developed a novel cost- effective knockdown method by designing an antisense oligonucleotides against the target mRNA and piggybacking with standard control morpholino to silence the gene of interest. Also, to perform knockdowns of the hox genes and test for the number of thrombocytes, the available techniques were both cumbersome or required breeding and production of fish where thrombocytes are GFP labeled. Therefore, I established a flow cytometry based method of counting the number of thrombocytes. I used mepacrine to fluorescently label the blood cells and used the white cell fraction. Standard antisense oligonucleotide designed to the central portion of each of the target hox mRNAs, was piggybacked by a control morpholino and intravenously injected into the adult zebrafish. The thrombocyte count was measured 48 hours post injection. In this study, I found that the knockdown of hoxc11b resulted in increased number of thrombocytes and knockdown of hoxa10b, hoxb2a, hoxc5a, and hoxd3a showed reduction in the thrombocyte counts. I then screened the other 47 hox genes in the zebrafish genome using flow sorting method and found that knockdown of hoxa9a and hoxb1a also resulted in decreased thrombocyte number. Further, I used the dye DiI, which labels only young thrombocytes at specific concentrations and observed that the knockdown of hoxa10b, hoxb2a, hoxc5a, hoxd3a, hoxa9a and hoxb1a, lead to a decrease in young thrombocytes; whereas hoxc11b knockdown lead to increase in number of young thrombocytes. Using bromodeoxyuridine, I also showed that there is increase in release of young thrombocytes into peripheral circulation in hoxc11b knockdown fish which suggests that hoxc11b significantly promotes cell proliferation rather effecting apoptosis. In conclusion, I found six hox genes that are positive regulators and one hox gene is a negative regulator for thrombocyte development.

GPR17, a uracil nucleotide cysteinyl leukotriene receptor, belongs to the GPCR (G protein coupled receptor) family. It has been shown recently that inhibiting this protein in the nervous system in mice can lead to blockage of oligodendrocyte maturation, which supports myelin repair. Interestingly, our laboratory found GPR17 in thrombocytes. However, we do not know whether it has any function in thrombocyte aggregation or the nature of the ligand. In this paper, we studied the role of GPR17 in hemostasis, which is a fundamental defense mechanism in the event of injury. Using zebrafish as a model system, our laboratory has studied specifically thrombocytes, which play a significant role in hemostasis. The major reasons to use zebrafish as a model system are that their thrombocytes are functionally equivalent to human platelets, the adult fish are amenable to knockdown experiments, and they are readily available in the market. This study was performed by using a piggy back knockdown method where we used a chemical hybrid of control morpholino and an antisense oligonucleotide sequence leads to the degradation the mRNA for GPR17. After knockdown GPR17 in thrombocytes, the percent difference of the thrombocytes aggregation between the control and knockdown blood samples was measured by flow cytometry. We used various thrombocyte agonists to study differences in aggregation between the control and knockdown blood samples. The study showed that knockdown of GPR17 resulted in no significant differences in percent thrombocyte aggregation between control and agonist treated samples except for a slight increase in collagen-treated samples. Thus, it appears that GPR17 has no significant role in hemostasis.

Transmembrane protein 59 (tmem59) is a gene that encodes a protein involved in autophagy and apoptosis in human. A previous study in zebrafish showed that tmem59 mRNA was several folds higher in thrombocytes than those found in red blood cells (RBCs). Therefore, we hypothesized that tmem59 has a role in thrombocytes function. We injected a hybrid of control vivo-morpholino (cVMO) and tmem59 specific antisense standard oligonucleotide (tmem59SO) into adult zebrafish to knockdown tmem59.This piggyback knockdown approach resulted in fish that had more bleeding in gill bleeding assay than the control fish. The thrombocytes fromtmem59 knockdown zebrafish aggregated faster with ADP and collagen agonists. Also, the number of blood cells was reduced after the knockdown of tmem59. We also found the effects of MS-222 anesthesia on hemostasis and found that the bleeding was reduced yielding less blood and the blood cell counts increased probably due to vasoconstriction of the blood vessels. In summary, we found tmem59 is a negative regulator of hemostasis and inferred that anesthesia should be avoided in hemostasis studies.

Um estudo prévio demonstrou em pacientes com choque séptico a presença de exossomos plasmáticos. Nossa hipótese é que exossomos circulantes poderiam contribuir para a disfunção contrátil da sepse. Foi colhido sangue de 55 pacientes com choque séptico. A incubação de corações isolados com exossomos de pacientes sépticos reduziu significantemente as derivadas da pressão ventricular e aumentou as concentrações de nitrato no miocárdio. A exposição de músculos papilares a exossomos reduziu a tensão desenvolvida. Concluímos que exossomos de pacientes sépticos induzem disfunção inotrópica em corações isolados e músculos papilares, possivelmente contribuindo para a disfunção miocárdica da sepse. / A previous report identified in plasma of septic shock patients the presence of exosomes. We hypothesized that circulating exosomes in sepsis could contribute to inotropic dysfunction. We collected blood samples from 55 patients with septic shock. Incubation of isolated heart preparations with exosomes induced a significant decrease in the derivatives of ventricular pressure and increased myocardial nitrate content. Exposure of isolated rat papillary muscles to exosomes reduced developed tension. We conclude that exosomes from septic patients induce myocardial dysfunction in isolated heart and papillary muscle preparations. Thus, they may contribute to myocardial dysfunction of sepsis.

Animais hematófagos possuem em sua saliva substâncias que permitem a fluidez do sangue, para o sucesso de sua alimentação. Com isso, têm sido descritos diversos componentes com atividades nos diferentes processos hemostáticos (coagulação, fibrinólise e agregação plaquetária). O complexo salivar da sanguessuga Haementeria depressa vem sendo estudado através de bioquímica clássica e análises transcriptômica e proteômica deste tecido determinaram o perfil dos transcritos e das proteínas produzidas. Dentre os transcritos mais abundantes foram encontrados três clones (H06A09, H06A02 e L02F02) que apresentaram 45%, 87% e 94% de similaridade ao LAPP, um inibidor de agregação plaquetária da sanguessuga Haementeria officinallis, a produção destes componentes pelo tecido foi confirmada pela análise proteômica. O LAPP é um inibidor que age pela via do colágeno e possui cerca de 14 kDa e pI de 4,0 e inibe a ligação da plaqueta ao colágeno tanto pelo epítopo do FvW quanto pelo domínio <font face=\"Symbol\">a2<font face=\"Symbol\">b1. Assim, o objetivo do presente trabalho foi clonar, expressar e caracterizar a proteína recombinante ativa, a partir do clone H06A09 para estudos de atividade desta molécula. Para obter a proteína recombinante de interesse inicialmente a clonagem do transcrito foi realizada com sucesso em vetor pAE, porém, a expressão em sistema procarioto apresentou alguns obstáculos já que a molécula não tinha atividade. Uma nova estratégia foi proposta, sendo realizada clonagem em vetor pPIC9K e expressão em sistema eucariótico (leveduras Pichia pastoris - GS115). Após a utilização de diferentes metodologias para estabelecimento das melhores condições para expressão neste sistema, foi eleito o protocolo onde a proteína recombinante era expressa a 28 °C, sob agitação de 260 rpm, e indução por 0,5% de Metanol a cada 24h, durante 72h de expressão. A molécula recombinante expressa e secretada foi submetida a diferentes metodologias para purificação, assim, determinou-se que a estratégia utilizada que melhor isolou a proteína foi a submissão do sobrenadante da expressão à diálise e concentração em sistema de ultrafiltração (Amicon 5 kDa Millipore) seguida de uma cromatografia de gel filtração em Superdex 75 (GE), sistema FPLC, com coleta fracionada. Ensaios de agregação plaquetária confirmaram a atividade inibitória da proteína recombinante tanto em sangue total como em PRP (plasma rico em plaqueta) e plaqueta lavada, especificamente quando o agonista era o colágeno, apresentando IC50 para PRP e plaqueta lavada de 20 e 712 ng, respectivamente. Ensaios por citometria de fluxo indicaram que a proteína recombinante, diferente do LAPP, age na inibição da agregação plaquetária induzida por colágeno, pela ligação à subunidade Ib<font face=\"Symbol\">a do complexo GPIb-IX-V, complexo este que usa o FvW como ponte entre a plaqueta e o colágeno, firmando assim a interação da plaqueta ao subendotélio e posterior agregação. Desta forma, o presente trabalho caracteriza o primeiro inibidor recombinante de agregação plaquetária pela via do colágeno proveniente de sanguessugas Haementeria depressa, e comprova que apesar de apresentar 45% de similaridade estrutural ao LAPP é um inibidor com características funcionais diferentes, e com grande potencial a ser estudado. / Hematophagous animals have in their saliva substances that maintain the blood fluidity to the success of their feeding. Therefore, components have been described by their activities in the hemostatic processes (coagulation, fibrinolysis and platelet aggregation).The salivary complex of Haementaria depressa leech has been studied by classical biochemical and transcriptomic and proteomic analysis of this tissue determined the profile of transcripts and proteins produced by it. Among the most abundant transcripts were found three clones (H06A09, H06A02 e L02F02) that showed 45%, 87% e 94% of similarity to LAPP, an inhibitor of platelet aggregation from Haementeria officinallis, the components production was confirmed by proteomic analysis. LAPP is a inhibitor that acts by collagen pathway and has around 14 kDa and pI of 4.0, and inhibits the binding of platelet to collagen by both the epitope domain of vWF as the <font face=\"Symbol\">a2<font face=\"Symbol\">b1. Thereby, the aim of this study was to clone, express and characterize the active recombinant protein from the clone H06A09 for studies of activity of this molecule. To obtain the recombinant protein initially cloning of transcript was successfully performed in pAE vector, however, the protein expressed in prokaryotic system presented some obstacles not presenting activity. A new strategy was proposed, being held in pPIC9K vector and expression in eukaryotic system - yeast Pichia pastoris (GS115). After using different methodologies to establish the best conditions for expression in this system, was elected the protocol where the recombinant protein was expressed in 28 °C, under agitation of 260 rpm, and 0.5% methanol induction every 24 hours during 72 hours of expression. The recombinant molecule was expressed in soluble portion and was subjected to differents methods for purification, so it was determined that the best strategy to isolation of the protein was the concentration and dialysis of the expression supernatant by ultrafiltration system (Amicon 5 kDa Millipore) followed by gel filtration chromatography on Superdex 75 (GE), FPLC system. Tests confirmed the platelet aggregation inhibitory activity of the recombinant protein in whole blood, PRP (platelet rich plasma) and in washed platelets, specifically when the agonist was collagen, with IC50 to PRP and washed platelet of 20 and 712 ng, respectively. Assays by flow cytometry indicated that the recombinant protein, different from LAPP, acts to inhibit platelet aggregation induced by collagen, by the binding to the Ib<font face=\"Symbol\">a subunit of the GPIb-IX-V complex, this complex uses the vWF as a bridge between the platelet and collagen, thus firming the interaction of the subendothelium and subsequent platelet aggregation. Thus, this study characterized the first recombinant inhibitor of platelet aggregation through collagen pathway from Haementeria depressa leeches, and proves that despite having 45% structural similarity to the LAPP is an inhibitor with different functional characteristics, and with great potential to be studied.

A adesão de plaquetas nas paredes dos vasos sanguíneos e subsequente agregação são eventos cruciais tanto na hemorragia e quanto na trombose. A hiperagregação (agregação excessiva) das plaquetas pode causar a formação de um trombo e a posterior oclusão dos vasos sanguíneos levando a um processo isquêmico. A terapia antiplaquetária com ácido acetilsalicílico reduz em até 25% o risco de infartos do miocárdio não-fatais, acidentes vasculares cerebrais isquêmicos ou mortes de causa vascular em pacientes de alto risco, independentemente do sexo ou idade. Para avaliar laboratorialmente a eficácia dessa terapêutica, o método mais utilizado é o teste de agregação plaquetária, que pode ser feito em duas metodologias, a turbidimétrica e a por impedância elétrica. Com esse cenário, o objetivo do estudo é comparar essas duas metodologias para a monitorização do tratamento. Para isso foram utilizadas amostras de sangue de 30 pacientes adultos (média de 42 anos) de ambos os sexos que fazem uso regular do fármaco e analisadas através das duas metodologias, tendo seus resultados analisados e comparados. Os resultados do estudo mostraram pouca diferença estatística significante (p<0,05) entre os dois métodos nos principais agentes estimulantes, indicando que o método de impedância elétrica pode ser utilizado em rotina laboratorial em substituição, ou em complementação, com a metodologia turbidimétrica para monitorar a terapia antiplaquetária a base de ácido acetilsalicílico / The adhesion of platelets in the blood vessel wall and subsequent aggregation are crucial events in both bleeding and thrombosis. The hyperaggregation (excessive aggregation) of platelets can cause the formation of a thrombus and subsequent occlusion of blood vessels leading to an ischemic process. Antiplatelet therapy with acetylsalicylic acyd reduces by 25% the risk of myocardial infarctions, non-fatal strokes or deaths from vascular causes in patients at high risk, regardless of sex or age. To laboratory evaluation of the effectiveness of this therapy, the method most used is the platelet aggregation test, which can be done in two methods, the turbidimetric and electrical impedance. With this scenario, the objective of the study is to compare these two methodologies for monitoring the treatment. For such purpose, blood samples from 30 adult patients (mean 42 years) of both sexes who make regular use of the drug was analyzed using the two methodologies, and their results was analyzed and compared. The studys results showed little difference statistically significant (p <0.05) between the two methods with the main stimulant agents, indicating that the method of electrical impedance can be used in routine laboratory instead or complementing the methodology of turbidimetric for monitor antiplatelet therapy by acetylsalicylic acyd

In order to simulate cellular blood, a coarse-grained spectrin-link (SL) red blood cell (RBC) membrane model is coupled with a lattice-Boltzmann (LB) based suspension solver. The LB method resolves the hydrodynamics governed by the Navier--Stokes equations while the SL method accurately models the deformation of RBCs under numerous configurations. This method has been parallelized using Message Passing Interface (MPI) protocols for the simulation of dense suspensions of RBCs characteristic of whole blood on world-class computing resources. Simulations were performed to study rheological effects in unbounded shear using the Lees-Edwards boundary condition with good agreement with rotational viscometer results from literature. The particle-phase normal-stress tensor was analyzed and demonstrated a change in sign of the particle-phase pressure from low to high shear rates due to RBCs transitioning from a compressive state to a tensile state in the flow direction. Non-Newtonian effects such as viscosity shear thinning were observed for shear rates ranging from 14-440 inverse seconds as well as the strong dependence on hematocrit at low shear rates. An increase in membrane bending energy was shown to be an important factor for determining the average orientation of RBCs, which ultimately affects the suspension viscosity. The shear stress on platelets was observed to be higher than the average shear stress in blood, which emphasizes the importance of modeling platelets as finite particles. Hagen-Poiseuille flow simulations were performed in rigid vessels for investigating the change in cell-depleted layer thickness with shear rate, the Fåhraeus-Linqvist effect, and the process of platelet margination. The process of platelet margination was shown to be sensitive to platelet shape. Specifically, it is shown that lower aspect ratio particles migrate more rapidly than thin disks. Margination rate is shown to increase with hematocrit, due to the larger number of RBC-platelet interactions, and with the increase in suspending fluid viscosity.

A computational model of thrombus initiation and aggrandizement was proposed. The model separated the thrombotic process into three mechanisms, including shear enhanced diffusivity, platelet margination, and platelet adhesion. The model indicates that transport mechanisms may be the rate limiting condition of thrombus formation at physiological shear rates and that at higher shear rates; platelet binding becomes the rate limiting condition. Additionally a wall shear rate of 20000 s-1 and above should be considered as a new criterion for prophylactic treatment of an atherosclerotic lesion.